← Eichor
Study identifier: NCT02103361 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

Condition: Psoriasis · Pregnancy · Psoriatic Arthritis  ·  Sponsor: University of California, San Diego

PhaseN/A
Planned participants200
Who can joinFemale, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live born infants for one year after birth. With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be relevant to a medication exposure during pregnancy, and these include both easily recognizable defects which are visible at birth, as well as more subtle or delayed defects that may not be readily identifiable without special expertise and observation beyond the newborn period.

This description comes directly from the study's public registry record.

Talk to the study team

Diana Johnson, MS  ·  877-311-8972  ·  d4johnson@ucsd.edu

Christina Chambers, PhD, MPH  ·  877-311-8972  ·  chchambers@ucsd.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San DiegoLa Jolla, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02103361